Comparison · NCT00762359-sae
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: serious adverse events. Trial comparisons, record NCT00762359-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00762359-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.119 | 0.0834 | 0.168 | wilson | |
| Risk in group 2 | 0.111 | 0.077 | 0.158 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00836 | -0.0506 | 0.0679 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.648 | 1.78 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.612 | 1.92 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Lansoprazole 15 mg QD than on Gefarnate 50 mg BID | 120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | 27 | 226 | EG000 |
| Group 2 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. | 26 | 234 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were summarized by onset date occurring on or after the first dose of double-blind study medication.
Source ClinicalTrials.gov
Trial
- Title
- A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
- NCT number
- NCT00762359
- Phases
- PHASE3
- Conditions
- Stomach Ulcer, Duodenal Ulcer
- Interventions
- Lansoprazole, Gefarnate
- Lead sponsor
- Takeda
- Results first posted
- 2011-05-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00762359?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00762359-sae